rheumatoid arthritis
Rheumatology · 2005–2025
59decisions
17medicines
12carried consumer input
26individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| etanercept Severe psoriatic arthritis, ankylosing spondylitis, severe active rheumatoid arthritis, severe chronic plaque psoriasis, and severe active juvenile idiopathic… | Jul 2025 | Recommended with restriction | none received |
| infliximab Multiple indications including rheumatoid arthritis, psoriatic arthritis, Crohn's disease in adults and children (6 to 17 years), refractory Crohn's disease,… | Jul 2025 | Recommended with restriction | input received Colitis Australia |
| infliximab Biosimilar to Remicade for rheumatoid arthritis, psoriatic arthritis, Crohn's disease (adults and children 6-17 years), refractory Crohn's disease, ankylosing… | Mar 2025 | Recommended with restriction | input received |
| infliximab Amendment to restriction level for continuing treatment of severe active rheumatoid arthritis, severe Crohn disease, severe chronic plaque psoriasis, severe… | Mar 2025 | Recommended with restriction | input received |
| tocilizumab Tocilizumab biosimilar requested for listing under the same circumstances as the reference brand Actemra for the treatment of active giant cell arteritis,… | Nov 2025 | Recommended with restriction | none received |
| methotrexate (as sodium) New formulation of methotrexate (as sodium) 2.5 mg and 10 mg tablets for listing under the same circumstances as the currently PBS-listed methotrexate tablets,… | Jul 2024 | Recommended | none received |
| tofacitinib Severe active rheumatoid arthritis (initial treatment, first continuing treatment, and subsequent continuing treatment) and severe psoriatic arthritis (initial… | Mar 2024 | Recommended with restriction | input received CreakyJoints Australia · Global Healthy Living Foundation Australia |
| upadacitinib Continuing treatment of severe active rheumatoid arthritis in adults who have demonstrated an adequate response to prior PBS-subsidised biological medicine… | Dec 2023 | Recommended with restriction | no section in document |
| adalimumab Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, hidradenitis suppurativa, chronic plaque psoriasis, ulcerative colitis, Crohn's disease, and… | Nov 2022 | Not recommended | 1 individuals |
| infliximab Treatment of severe active rheumatoid arthritis (RA) with loading doses of 120 mg subcutaneously at weeks 0, 1, 2, 3 and 4, followed by maintenance dosing… | Nov 2022 | Recommended with restriction | input received |
| etanercept Listing of etanercept injection 50 mg in 1 mL single use dose-dispenser cartridges for the same indications as currently listed etanercept pre-filled syringes:… | Jul 2021 | Recommended with restriction | unclear |
| etanercept Severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, and juvenile idiopathic arthritis. | Nov 2021 | Recommended | unclear |
| etanercept Support for uptake of etanercept biosimilar (Brenzys) in patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and chronic plaque… | Dec 2020 | Not recommended | no section in document |
| infliximab Treatment of adults with severe active rheumatoid arthritis, ankylosing spondylitis, severe refractory Crohn's disease, complex refractory fistulising Crohn's… | Nov 2020 | Recommended with restriction | input received Colitis Australia · Parallel- Group |
| upadacitinib Treatment of severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying… | Nov 2020 | Noted | none received |
| upadacitinib Treatment of severe active rheumatoid arthritis in patients with inadequate response to conventional disease-modifying anti-rheumatic drugs (cDMARDs). | Nov 2019 | Recommended with restriction | none received |
| upadacitinib Severe active rheumatoid arthritis in patients with inadequate response to at least 6 months of intensive conventional disease-modifying antirheumatic drugs… | Nov 2019 | Recommended | none received |
| adalimumab Severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, juvenile idiopathic arthritis, severe… | Jul 2018 | Recommended | 1 individuals |
| tocilizumab Treatment of severe active rheumatoid arthritis (RA) in adult patients. | Jul 2018 | Recommended with restriction | none received |
| adalimumab Rheumatoid arthritis (RA) indication for which the reference product Humira is currently PBS listed. | Jul 2018 | Recommended | 1 individuals |
| baricitinib Treatment of severe active rheumatoid arthritis in adult patients who have responded inadequately, or who are intolerant, to one or more disease-modifying… | Mar 2018 | Recommended | none received |
| etanercept Biosimilar etanercept for multiple indications including severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic… | Mar 2018 | Recommended with restriction | none received |
| etanercept Proposed changes to the listing of etanercept (Brenzys brand) to support biosimilar uptake, including changes to authority requirements and treatment cycle… | Nov 2018 | Deferred | none received |
| sarilumab Severe active rheumatoid arthritis in adult patients who have had an inadequate response to conventional disease-modifying anti-rheumatic drugs (cDMARDs). | Nov 2018 | Recommended with restriction | none received |
| etanercept severe active rheumatoid arthritis, ankylosing spondylitis, severe psoriatic arthritis, and severe chronic plaque psoriasis | Aug 2017 | Recommended with restriction | no section in document |
| auranofin Alternative capsule formulation of auranofin for patients with rheumatoid arthritis, particularly those with early or mild disease, or those with suboptimal… | Jul 2017 | Recommended | none received |
| baricitinib Treatment of severe active rheumatoid arthritis in patients with inadequate response to at least 6 months of intensive DMARD therapy. | Jul 2017 | Deferred | 21 individuals Creaky Joints Australia |
| certolizumab pegol Treatment of severe active rheumatoid arthritis, severe psoriatic arthritis, and active ankylosing spondylitis. | Mar 2017 | Recommended with restriction | none received |
| infliximab Change to initial and continuing treatment restrictions for the biosimilar brand of infliximab (Renflexis) for severe active rheumatoid arthritis, ankylosing… | Nov 2017 | Recommended with restriction | none received |
| baricitinib Treatment of severe rheumatoid arthritis (RA). | Nov 2017 | Deferred | none received |
| auranofin Treatment of rheumatoid arthritis. This submission requested an increase in the maximum quantity from 60 to 100 tablets per pack to address supply shortage. | Jul 2016 | Recommended | no section in document |
| etanercept Biosimilar to etanercept for all indications for which etanercept (Enbrel) is currently PBS-listed: rheumatoid arthritis, ankylosing spondylitis, psoriatic… | Jul 2016 | Recommended | input received |
| certolizumab pegol Loading dose administration (weeks 0, 2, and 4) for patients with ankylosing spondylitis, severe psoriatic arthritis, and severe active rheumatoid arthritis. | Mar 2016 | Recommended with restriction | no section in document |
| tocilizumab Treatment of severe active rheumatoid arthritis (RA) in adult patients, delivered by subcutaneous injection. | Mar 2016 | Recommended with restriction | none received |
| infliximab Biosimilar to Remicade for multiple indications including rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, ulcerative colitis, and… | Nov 2016 | Recommended | none received |
| infliximab Biosimilar to Remicade for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, ulcerative colitis, and Crohn's disease. | Jul 2015 | Recommended with restriction | 2 individuals |
| tofacitinib Severe active rheumatoid arthritis in patients who have failed intensive treatment with disease-modifying antirheumatic drugs (DMARDs) including methotrexate. | Mar 2015 | Recommended with restriction | none received |
| abatacept Treatment of severe active rheumatoid arthritis. This submission concerns a new autoinjector presentation of the existing abatacept 125 mg/mL injection. | Nov 2015 | Recommended with restriction | none received |
| naproxen and esomeprazole Symptomatic treatment of osteoarthritis, rheumatoid arthritis or ankylosing spondylitis in patients who require an NSAID and are at increased risk of… | Jul 2013 | Not recommended | no section in document |
| tocilizumab Amendment to PBS restriction for severe active rheumatoid arthritis; specifically, to allow tocilizumab monotherapy in patients who can tolerate methotrexate… | Jul 2013 | Recommended | no section in document |
| Naproxen and esomeprazole Symptomatic treatment of osteoarthritis, rheumatoid arthritis or ankylosing spondylitis in a patient who requires a non-steroidal anti-inflammatory drug… | Mar 2012 | Not recommended | unclear |
| naproxen and esomeprazole Symptomatic treatment of osteoarthritis, rheumatoid arthritis or ankylosing spondylitis in patients who require an NSAID and are at high risk of… | Mar 2012 | Not recommended | unclear |
| naproxen and esomeprazole Symptomatic treatment of osteoarthritis, rheumatoid arthritis or ankylosing spondylitis in patients who require an NSAID and are at high risk of… | Nov 2012 | Not recommended | unclear |
| certolizumab pegol treatment of severe active rheumatoid arthritis in adult patients who meet certain criteria, including those who have failed to achieve an adequate response to… | Mar 2010 | Recommended | no section in document |
| golimumab treatment of adult patients with severe active rheumatoid arthritis who meet certain criteria, in combination with methotrexate | Mar 2010 | Recommended with restriction | no section in document |
| tocilizumab treatment of severe active rheumatoid arthritis; first line use in combination with methotrexate or as monotherapy for patients who have failed to demonstrate… | Mar 2010 | Recommended with restriction | no section in document |
| certolizumab pegol Treatment of severe active rheumatoid arthritis in adult patients who have failed to achieve an adequate response to methotrexate and other disease-modifying… | Mar 2010 | Recommended with restriction | no section in document |
| golimumab Treatment of adult patients with severe active rheumatoid arthritis who have inadequate response to disease-modifying anti-rheumatic drug (DMARD) therapy,… | Mar 2010 | Recommended with restriction | no section in document |
| tocilizumab treatment of severe, active rheumatoid arthritis in combination with methotrexate or other disease-modifying anti-rheumatic drugs (DMARDs) | Jul 2009 | Recommended with restriction | no section in document |
| The review was for the clinical and cost-effectiveness data of biological disease-modifying anti-rheumatic drugs (bDMARDs) for the treatment of severe, active… | Dec 2009 | Noted | no section in document |
| abatacept, anakinra, adalimumab, etanercept, infliximab, rituximab Treatment of severe, active rheumatoid arthritis in patients who have failed to respond to non-biological disease-modifying antirheumatic drugs (DMARDs). | Dec 2009 | Noted | no section in document |
| tocilizumab Initial and continuing treatment, as monotherapy, of severe active rheumatoid arthritis in patients who have failed to demonstrate a response to TNF-alfa… | Nov 2009 | Recommended with restriction | no section in document |
| etanercept For treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) in patients with ≥10 tender and swollen joints or ≥2 major affected joints, with… | Jul 2008 | Recommended | no section in document |
| Infliximab Extension of current Section 100 rheumatoid arthritis restriction to allow dose escalation to 5 mg/kg for patients who have failed to respond to an initial 3… | Jul 2008 | Recommended | no section in document |
| etanercept Extension of PBS listing for rheumatoid arthritis (RA) and psoriatic arthritis (PsA) to include patients with ≥10 tender and swollen joints or ≥2 major… | Jul 2008 | Not recommended | no section in document |
| rituximab patients with severe active rheumatoid arthritis (RA) who have received prior treatment with a tumour necrosis factor antagonist (anti-TNF) | Mar 2007 | Recommended with restriction | no section in document |
| abatacept Treatment, in combination with methotrexate, of adults with severe active rheumatoid arthritis who have failed prior disease modifying anti-rheumatic drug… | Nov 2007 | Recommended | no section in document |
| etanercept treatment, in combination with methotrexate, of adult patients with severe active rheumatoid arthritis who are at high risk of erosive disease to slow… | Nov 2005 | Not recommended | no section in document |
| etanercept Treatment in combination with methotrexate of adult patients with severe active rheumatoid arthritis who are at high risk of erosive disease in order to slow… | Nov 2005 | Not recommended | no section in document |
Who spoke
Colitis Australia · Parallel- Group · CreakyJoints Australia · Global Healthy Living Foundation Australia · Creaky Joints Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 12 of 38 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.